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Background and purpose   There is increasing awareness 
that non-steroidal anti-inﬂammatory drugs (NSAIDs), 
and especially the cyclooxygenase-2 (COX-2) selective 
ones, may retard bone healing. We have used NSAIDs 
(indomethacin for at least 7 days) to prevent hetero-
topic ossiﬁcation after acetabular reconstructions using 
impacted bone grafts. The long-term clinical results have 
been satisfying, making it difﬁcult to believe that there is 
an important negative effect of NSAIDs on graft incor-
poration. We studied the effect of two different NSAIDs 
on bone and tissue ingrowth in a bone chamber model 
in goats, using autograft, rinsed allograft, and allograft 
that had been rinsed and subsequently irradiated.
Methods   9 goats received no NSAIDs, 9 received keto-
profen, and 9 received meloxicam—all for 6 weeks. In 
each goat 6 bone chambers were implanted: 2 ﬁlled with 
autograft, 2 with rinsed allograft, and 2 with allograft 
that had been rinsed and irradiated. The amount of 
bone ingrowth and total tissue ingrowth was compared 
between the groups. 
Results   There were no statistically signiﬁcant differ-
ences in bone ingrowth between the different groups. 
Also, no differences in bone ingrowth were found with 
respect to the type of graft used. Furthermore, there was 
no statistically signiﬁcant difference in the total amount 
of ingrowth of ﬁbrous tissue between the treatment 
groups.
Interpretation   No differences in bone ingrowth in 
titanium bone chambers could be detected with both 
ketoprofen and meloxicam compared to untreated con-
trol animals. This conﬁrms our hypothesis that the effect 
of NSAIDs on the incorporation and ingrowth of bone 
graft is limited.                       ■
There is both experimental and clinical evidence of 
inhibition of new bone formation by NSAIDs (both 
selective and non-selective) (Goodman et al. 2002, 
Harder and An 2003, Simon and O’Connor 2007). 
NSAIDs inhibit bone ingrowth in porous implants 
(Trancik et al. 1989, Goodman et al. 2002), delay 
fracture healing (Simon and O’Connor 2007), 
inhibit spinal fusion in rats (Dimar et al. 1996), and 
inhibit experimental bone induction (Persson et al. 
2005b). Clinically, NSAIDs have been found to 
retard healing of diaphyseal fractures (Burd et al. 
2003) and spinal fusions (Glassman et al. 1998). 
NSAIDs are also effective in preventing hetero-
topic ossiﬁcation (HO) after total hip arthroplasty 
(Neal et al. 2000), strongly suggesting that these 
drugs also have effects on human bone formation 
on ectopic places. Theoretically, these NSAIDs 
inhibit bone restoration, which may result in a less 
stable or unstable implant (Persson et al. 2005a). 
The effect of NSAIDs could be even more dev-
astating if they are combined with bone grafts to 
reconstruct bone defects. An inhibitory effect of 
NSAIDs on bone repair could also jeopardize the 
ingrowth into these grafts. 
We have used NSAIDs (indomethacin for at 
least 7 days) to prevent heterotopic ossiﬁcation 
with acetabular reconstructions in both primary 
and revision hip surgery. The long-term clinical 
results are satisfying, making it difﬁcult to believe 
that NSAIDs have an important negative effect on 
graft incorporation (Welten et al. 2000, Schreurs 
et al. 2004). Also, in a study on the outcome of 
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minimum follow-up of 10 years, the administration 
of indomethacin did not appear to inﬂuence long-
term results (Schreurs et al. 2005).
We studied the effect of 2 different NSAIDs on 
bone and tissue ingrowth in a bone chamber model 
in goats using autograft, rinsed allograft, and rinsed 
and subsequently irradiated allograft. We hypoth-
esized that the effect of NSAIDs on the incorpora-
tion of bone grafts is limited.
Materials and methods
Experimental design
30 mature Dutch milk goats (Capra hircus sana) 
(48–61 kg) were obtained from the Central Animal 
Laboratory, Nijmegen, the Netherlands. 
Allograft bone was obtained from the sternum 
of 3 donor goats; the other 27 goats were divided 
into 3 groups. The ﬁrst group did not receive any 
NSAID, the second group received ketoprofen (a 
non-selective NSAID) (2.2 mg/kg) once daily sub-
cutaneously, and the third group received meloxi-
cam (COX-2 preferential) (0.5 mg/kg) once daily 
subcutaneously. The treatment period was 6 weeks 
for all goats. The treatment regimen for both keto-
profen and meloxicam in goats was based on the 
literature (Moses and Bertone 2002, Arifah et 
al. 2003). All procedures were approved by the 
Animal Ethics Committee of Radboud University, 
Nijmegen, the Netherlands.
Preparation of grafts
3 donor goats were used to obtain allograft from 
the sternum. These goats were killed by an over-
dose of pentobarbital and the sternum was excised 
under aseptic conditions. All spongious bone from 
the sternum was retrieved and rinsed with ster-
ile saline using a high-pressure pulsatile lavage 
system (SurgiLav Plus; Stryker Nederland BV, 
Waardenburg, the Netherlands). The bone was 
subsequently pooled and divided in 2 parts. The 
ﬁrst part was used without further processing, and 
the second part was irradiated with 25 kGy using 
a 60Co gamma-ray source (Isotron BV, Ede, the 
Netherlands) at a temperature of –78.5°C (dry ice). 
Both allograft and irradiated allograft were stored 
at –80°C and thawed just before implantation.
Implants
We used the bone conduction chamber (BCC), 
which is a model for membranous ossiﬁcation 
(Aspenberg and Wang 1993, Wang and Aspenberg 
1994). The BCC consists of a titanium screw with 
a cylindrical interior space. It is made up of two 
threaded half-cylinders held together by a hexago-
nal closed screw cap. The interior of the chamber 
has a diameter of 2 mm, and a length of 7.5 mm. 
There are two ingrowth openings for bone ingrowth 
located at the bone end of the chamber. Originally 
developed as a rat model, the BCC was adapted by 
us for use in goats. The threaded end of the implant 
is screwed into the bone, allowing direct contact 
of the ingrowth openings with the endosteal transi-
tion from marrow into bone. To accomplish this in 
goats, a 1-mm-thick plate was inserted into the cap 
to lower the ingrowth openings through the cortex 
(van der Donk et al. 2001, Hannink et al. 2007).
Surgical procedure
Anesthesia was accomplished by intravenous 
administration of pentobarbital (CEVA Santé Ani-
male, Maasluis, the Netherlands) (0.5 mL/kg) and 
maintained after intubation with nitrous oxide, 
oxygen, and isoﬂurane (1.5–2%). In all 27 goats, 
autograft was obtained from the right femoral con-
dyle under aseptic conditions. A longitudinal inci-
sion was made along the lateral epicondyle, and 
just ventral to the iliotibial tract a hole was made 
with a hollow drill of 7.3 mm and a plug of cortico-
spongious bone was retrieved. The spongious part 
of this plug was used as autograft. 
The goats received 3 chambers at each side in 
the cortical bone of the proximal medial tibia. 1 
chamber at each side was ﬁlled with autologous 
graft, 1 with rinsed allograft, and the third with 
irradiated, rinsed allograft. A longitudinal incision 
was made in the skin and fascia over the medial 
side of the proximal tibia. After raising the perios-
teum, a hole was drilled through the medial cortex 
approximately 4 cm from the joint cleft using a 
3.1-mm drill. The hole was tapped and bone debris 
from drilling was removed. The bone chamber was 
screwed in manually. The second bone chamber 
was placed at a distance of 10 mm from the ﬁrst 
one, and the third was placed 10 mm lower. This 
was repeated for the other side. The positions of 
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tions in different cases, to avoid linking of the dif-
ferent variables (for example, all autografts in the 
proximal position). The subcutaneous layer and 
the skin were sutured. All animals were allowed 
unrestricted movement in their cages and had free 
access to water and food after the operation. After 
the implantation procedure, the animals received 
subcutaneous ampicillin (15 mg/kg/48 h) 3 times. 
Evaluation
After 6 weeks, all goats were killed with an over-
dose of pentobarbital. Tibiae were removed, and 
the bone chambers with surrounding cortex were 
ﬁxed in 4% buffered formalin. After 1 day, the 
content was removed from the chambers and ﬁxed 
additionally. The specimens were dehydrated 
using ethanol and embedded in poly(methyl meta-
crylate) (PMMA). The specimens were cut with a 
microtome parallel to the longitudinal axis of the 
chamber. Sections were taken at 0, 300, and 600 
µm from the center of the specimens, each section 
being 5 µm thick. The sections were stained with 
hematoxylin and eosin, and with Goldner-Masson 
trichrome for routine histology. All sections in 
each experiment were investigated in random 
order. 
Histomorphometric analysis was performed 
using interactive computer-controlled image 
analysis (analySIS; Soft Imaging System GmbH, 
Münster, Germany). The bone ingrowth distance 
in each slide was calculated by dividing the area 
of new bone by the width of the specimen. In all 
specimens, marrow cavities surrounded by bone 
were included in the bone area. The mean of the 
3 sections at 0, 300, and 600 µm from the center 
yielded a value for the specimen. The total tissue 
ingrowth distance, which is the distance from the 
end of the ingrowth to the ﬁbrous ingrowth frontier, 
was measured in the same way as bone ingrowth 
(Tägil 2000) .
Statistics
We applied two outcome measures: ﬁbrous tissue 
ingrowth and bone ingrowth. Each was possibly 
related to medication (none, ketoprofen, or meloxi-
cam), graft type (autograft, rinsed allograft, or irra-
diated rinsed allograft), side (left or right leg), and 
position of the bone chamber (proximal, distal, or 
middle).
For each of the two outcome measures, a general 
linear model for repeated measurements (in one 
animal) was postulated. We assumed that there was 
a correlation between all 6 variables in each goat. 
These models were subsequently analyzed with 
PROC MIXED software (SAS International, Hei-
delberg, Germany) and p-values less than 0.05 were 
considered to be signiﬁcant. The smallest relevant 
difference in ingrowth was set at 0.8 mm. The study 
was designed to have 80% power in detecting this dif-
ference of 0.8 mm between the means of all groups, 
and a standard deviation of this mean of 0.5 mm.
Results
Clinical evaluation
1 goat (not on NSAIDs) died after 2 weeks, due 
to an unknown pregnancy and complicated deliv-
ery. All other goats performed well, with full load-
ing of their legs on the ﬁrst day after surgery. At 
preparation of the grafts, 1 bone chamber was lost 
(autograft from the ketoprofen group), resulting in 
a total of 155 samples.
Histological analysis
17 of the bone chambers showed no ingrowth or 
only fatty tissue and no ﬁbrous tissue or bone: 5 
in the group without medication (2 autografts and 
3 irradiated autografts), 7 in the ketoprofen group 
(5 autografts and 2 irradiated allografts), and 5 in 
the meloxicam group (1 autograft, 2 allografts, and 
2 irradiated allografts). The remaining 138 speci-
mens showed a typical ingrowth pattern. Nonvas-
cularized remnants of the graft were present in the 
top of the chamber. A ﬁbrous ingrowth zone was 
present between the graft and the newly formed 
bone, and there was a zone of newly formed bone 
located at the bottom of the chamber (Figure 1). In 
all treatment groups, the newly formed bone con-
sisted of immature woven bone in a ﬁbrovascular 
stroma (Figures 2 and 3). 
Histomorphometry
No differences in bone growth (p = 0.5) or ﬁbrous 
tissue ingrowth (p = 0.6) were found between the 
different medication groups (Table 1), including 
the group that did not receive any NSAIDs (Tables 
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No differences in bone ingrowth were found 
with respect to graft type (p = 0.4), position of the 
bone chamber (p = 0.6), or operated leg (p = 0.6) 
(Table 3). 
 In contrast, we found a higher amount of total 
tissue ingrowth in the irradiated, rinsed bone graft 
than in the other 2 graft types/treatments (p = 
0.01), no left-to-right difference (p = 0.05), and a 
higher total amount of tissue in the proximal bone 
chamber as compared to the middle and distal ones 
(p = 0.001). No differences in total tissue ingrowth 
were found when comparing the different medica-
tion groups (p = 0.6). 
Discussion
Although there is sufﬁcient evidence that NSAIDs 
cause reduced fracture healing and bone ingrowth 
in smaller animals, the effects of these drugs on 
bone graft incorporation in humans and larger 
animals appears to be limited. The good results of 
THA despite the use of NSAIDs as prophylaxis for 
HO makes it difﬁcult to believe that the effect of 
NSAIDs on bone ingrowth is as large as it is in 
smaller animals.
We found no difference in bone ingrowth in tita-
nium bone chambers in the goat, irrespective of 
whether the animals were treated with ketoprofen 
or meloxicam or no medication at all. Furthermore, 
there was comparable ingrowth of bone irrespec-
Figure 1. Example of typical bone ingrowth in a bone 
chamber (hematoxylin and eosin). This goat received 
meloxicam and a rinsed allograft was used. Nonvascular-
ized remnants of the graft (G) can be seen at the top of the 
chamber. A ﬁbrous ingrowth zone (F) can be seen between 
the graft and the newly formed bone, and a zone of newly 
formed bone (B) can be seen at the bottom of the chamber. 
Magniﬁcation 12.5×.
Figure 2. Typical histological section from a sample of a 
graft from a goat that received ketoprofen (hematoxylin 
and eosin). Newly formed woven bone (NB) in a ﬁbrovas-
cular stroma (FS) can be seen, with vital osteoblasts (*) 
and osteoclasts (C) surrounding the newly formed bone. 
Magniﬁcation 50×.
Figure 3. Typical histological section from a sample of a 
graft from a goat that received meloxicam (hematoxylin 
and eosin). New woven bone (NB) in a ﬁbrovascular stroma 
(FS), with osteoblasts (*) and osteoclasts (C) comparable 
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tive of whether an autograft, rinsed allograft, or 
irradiated rinsed allograft was used. The ﬁndings 
of the same amount of ingrowth in rinsed allograft 
and autograft are similar to the ﬁndings of van 
der Donk et al. (2003), who found that with rins-
ing, total tissue ingrowth increased in the allograft 
group to approach that of autografts. The effect of 
lipid extraction from allografts, which enhances 
bone ingrowth, has been described before by 
Thorén et al. (1995). The similar amounts of 
ingrowth in rinsed allografts and irradiated, rinsed 
allografts are in line with the ﬁndings of Hannink 
et al. (2007).
The bone chamber model we used was developed 
by Aspenberg and Wang (1993). In this animal 
model, a single factor can be changed to evaluate 
its effect on bone ingrowth. Although the effect of 
physical load cannot be studied in this model, it is 
valid for detecting the effects of bone substitutes 
and signaling molecules involved in bone metabo-
lism that arise under unloaded conditions (Tägil 
2000). Most bone chamber studies have been per-
formed in smaller animals, especially rats and mice 
(Goodman et al. 2002, Gerstenfeld et al. 2003, 
Simon and O’Connor 2007). It is possible that the 
pharmacological and pathophysiological regula-
tion of COX or the properties of the isoenzymes 
in different animal species differ; thus, when anti-
inﬂammatory effects of NSAIDs are determined 
in animal experiments based on COX inhibition, 
species differences should be taken in to account 
(Cheng et al. 1998). The ingrowth itself in this 
animal model is comparable in rats and goats (van 
der Donk et al. 2001). We used goats, because we 
believe that the bone metabolism in goats is similar 
to the bone metabolism of humans, relative to the 
metabolism in mice or rats. Furthermore, the phar-
macokinetics and pharmacodynamics of the drugs 
we used are already known (Moses and Bertone 
2002, Arifah et al. 2003). 
Although we wanted to use a COX-2 selective 
NSAID, we used the COX-2 preferential drug 
meloxicam because this is the only one for which 
the pharmacokinetics and pharmacodynamics have 
Table 1. Bone ingrowth and ﬁbrous ingrowth, mm (SD)
 No medication Ketoprofen Meloxicam
 Bone Tissue Bone Tissue Bone Tissue
Autograft 0.5 (0.6) 3.9 (1.1) 1.0 (1.1) 4.5 (1.6) 0.9 (1.0) 4.1 (1.2)
Allograft 0.8 (0.8) 4.1 (1.2) 1.0 (1.8) 4.2 (1.3) 1.0 (0.8) 4.1 (1.1)
Irradiated 
  allograft 1.0 (1.0) 4.1 (1.5) 0.8 (0.7) 4.5 (1.4) 1.1 (0.9) 4.5 (1.3)
Table 2. Bone ingrowth in the different medication groups
Medication Difference observed, in mm 95% CI P-value
No medication vs. ketoprofen –0.14  -0.66–0.38 0.6
 (no medication lower than ketoprofen) 
No medication vs. meloxicam –0.3  -0.82–0.22 0.2
 (no medication lower than meloxicam) 
Ketoprofen vs. meloxicam –0.16  -0.69–0.34 0.5
 (ketoprofen lower than meloxicam) 
Table 3. Tests of ﬁxed effects; relationship between bone 
ingrowth and graft type, medication, side, and position 
of the bone chamber 
 Degrees of F-value P-value
  freedom
Graft type 2 0.92 0.4
Medication 2 0.73 0.5
Side 1 0.28 0.6
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been studied in the goat. For the same reason, we 
chose ketoprofen as a non-selective NSAID (Moses 
and Bertone 2002, Arifah et al. 2003). We adminis-
tered the drugs for 6 weeks, based on the study by 
van der Donk et al. (2001) who found representa-
tive ingrowth in goats after 6 weeks.
Our data from this animal study should certainly 
be interpreted with caution. The data on the effects 
of NSAIDs on ﬁxation of total hip prostheses in 
humans are conﬂicting. Ince at al. (2007) found no 
difference in loosening of uncemented acetabular 
components after 5 years when comparing groups 
that received indomethacin, postoperative irradia-
tion, or no prophylaxis, for heterotopic ossiﬁca-
tion. Similarly, Kjaersgaard-Andersen et al. (1991) 
could not detect a difference in loosening or lucen-
cies between patients who received indomethacin 
and the ones who did not. On the other hand, Pers-
son et al. (2005a) found a trend of higher revision 
rates in an indomethacin treatment group than in 
patients who did not receive any NSAIDs after 10 
years of follow-up.
Based on our study, we conclude that there was 
no detectable difference when using either keto-
profen and meloxicam in titanium bone chambers 
in goats loaded with fresh autograft, allograft, or 
irradiated allograft. Extrapolation of these results 
to the human situation must be done with cau-
tion. On the the basis of these data and clinical 
data, however, the effect of NSAIDs on bone graft 
ingrowth may be limited. 
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